Coincubation as miR-Loading Strategy to Improve the Anti-Tumor Effect of Stem Cell-Derived EVs.

anti-tumor cancer stem cells coincubation exosomes extracellular vesicle engineering loading microRNA

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
08 Jan 2021
Historique:
received: 09 12 2020
revised: 29 12 2020
accepted: 04 01 2021
entrez: 12 1 2021
pubmed: 13 1 2021
medline: 13 1 2021
Statut: epublish

Résumé

Extracellular vesicles are considered a novel therapeutic tool, due to their ability to transfer their cargoes to target cells. Different strategies to directly load extracellular vesicles with RNA species have been proposed. Electroporation has been used for the loading of non-active vesicles; however, the engineering of vesicles already carrying a therapeutically active cargo is still under investigation. Here, we set up a coincubation method to increase the anti-tumor effect of extracellular vesicles isolated from human liver stem cells (HLSC-EVs). Using the coincubation protocol, vesicles were loaded with the anti-tumor miRNA-145, and their effect was evaluated on renal cancer stem cell invasion. Loaded HLSC-EVs maintained their integrity and miR transfer ability. Loaded miR-145, but not miR-145 alone, was protected by RNAse digestion, possibly due to its binding to RNA-binding proteins on HLSC-EV surface, such as Annexin A2. Moreover, miR-145 coincubated HLSC-EVs were more effective in inhibiting the invasive properties of cancer stem cells, in comparison to naïve vesicles. The protocol reported here exploits a well described property of extracellular vesicles to bind nucleic acids on their surface and protect them from degradation, in order to obtain an effective miRNA loading, thus increasing the activity of therapeutically active naïve extracellular vesicles.

Identifiants

pubmed: 33429869
pii: pharmaceutics13010076
doi: 10.3390/pharmaceutics13010076
pmc: PMC7826638
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro (AIRC)
ID : project IG2015 16973

Références

Oncotarget. 2018 Nov 16;9(90):36151-36165
pubmed: 30546834
FEBS Lett. 2015 Dec 21;589(24 Pt B):4071-8
pubmed: 26632510
J Control Release. 2016 Jun 28;232:51-61
pubmed: 27072025
Nucleic Acids Res. 2012 Sep 1;40(17):e130
pubmed: 22618874
J Extracell Vesicles. 2017 Mar 7;6(1):1286095
pubmed: 28326170
Mol Ther Methods Clin Dev. 2019 Jan 09;13:133-144
pubmed: 30788382
Mol Ther. 2017 Jul 5;25(7):1580-1587
pubmed: 28392161
Stem Cells. 2006 Dec;24(12):2840-50
pubmed: 16945998
Oncotarget. 2015 Oct 20;6(32):32774-89
pubmed: 26416415
Ann Transl Med. 2017 Jan;5(1):23
pubmed: 28164108
J Hematol Oncol. 2015 Oct 29;8:122
pubmed: 26514126
PLoS One. 2016 Sep 29;11(9):e0163665
pubmed: 27684368
Pharmaceutics. 2020 Oct 16;12(10):
pubmed: 33081417
Sci Transl Med. 2019 May 15;11(492):
pubmed: 31092696
Int J Mol Sci. 2019 May 14;20(10):
pubmed: 31091699
Int J Cancer. 2020 Sep 15;147(6):1694-1706
pubmed: 32064610
J Control Release. 2013 Nov 28;172(1):229-238
pubmed: 23994516
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
Genes Chromosomes Cancer. 2012 Jul;51(7):707-16
pubmed: 22492545
Int J Cancer. 2019 Jan 15;144(2):322-333
pubmed: 30110127
Mol Ther. 2018 Mar 7;26(3):774-783
pubmed: 29456019
FASEB J. 2008 Oct;22(10):3696-705
pubmed: 18614581
Stem Cell Rev Rep. 2018 Apr;14(2):236-246
pubmed: 29185191
Stem Cells. 2012 Sep;30(9):1985-98
pubmed: 22736596
Int J Nanomedicine. 2018 Jan 30;13:585-599
pubmed: 29430178
Cells. 2020 Sep 29;9(10):
pubmed: 33003285
Pharm Res. 2017 May;34(5):1053-1066
pubmed: 28315083
Int J Nanomedicine. 2020 Apr 01;15:2323-2335
pubmed: 32308384
Mol Ther. 2013 Jan;21(1):185-91
pubmed: 23032975
J Control Release. 2018 Jan 10;269:10-14
pubmed: 29126999
Nat Rev Mol Cell Biol. 2019 Sep;20(9):509-510
pubmed: 31324871
Semin Cancer Biol. 2020 Sep 22;:
pubmed: 32977006

Auteurs

Alessia Brossa (A)

Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.
Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy.

Marta Tapparo (M)

Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy.
Department of Medical Science, University of Torino, 10126 Torino, Italy.

Valentina Fonsato (V)

Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy.
Society for Business Incubator and Tech Transfer, University of Torino, 10126 Torino, Italy.

Elli Papadimitriou (E)

Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.
Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy.

Michela Delena (M)

Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy.

Giovanni Camussi (G)

Department of Medical Science, University of Torino, 10126 Torino, Italy.

Benedetta Bussolati (B)

Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.
Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy.

Classifications MeSH